louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04196829: Staining Potential and Caries Arresting Effect of Silver Diamine Fluoride⁄Potassium Iodide and Silver Diamine Fluoride
Official title: Comparative Evaluation of Staining Potential and Caries Arresting Effect of Silver Diamine Fluoride⁄Potassium Iodide and Silver Diamine Fluoride in Carious Primary Anterior Teeth
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Dental Caries in Children
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2019-12-12
Enrollment: 15
Sex: ALL
Minimum age (years): 3
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the main objective of this study is to evaluate staining potential and Caries Arresting Effect of silver diamine fluoride⁄potassium Iodide and silver diamine fluoride in carious anterior primary teeth

Detailed description: Despite increased attention on caries prevention, not all children receive preventive treatments and large numbers still experience tooth decay. Primary care providers have had little option other than invasive and costly specialist treatment in the hospital under general anesthesia. In this context, there is interest in simple treatments to halt progress of carious lesions after tooth decay onset. Among these simple treatments is silver diamine fluoride (SDF) treatment. The major drawback to SDF treatment has been its black staining, which has limited its use. To counter the staining, researchers have tested SDF treatment immediately followed with application of saturated solution of potassium iodide (KI).

Eligibility criteria: Inclusion Criteria:

* Children with carious primary anterior teeth.
* Children with no spontaneous pain

Exclusion Criteria:

* Tooth mobility
* Signs of pulpal or periapical infection
* Severe medical conditions that would not allow management in the clinic
* Sensitivity to silver or other heavy-metal ions
* Presence of any gingival or perioral ulceration or stomatitis

Primary outcomes:
measure: staining potential
timeFrame: base line and Immediately after material application
Secondary outcomes:
measure: caries arresting effect
timeFrame: 3 months, 6 moths, 9 months, 12 months
Other outcomes:
measure: post operative pain
timeFrame: 3 months, 6 moths, 9 months, 12 months
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
affiliation: Lecturer, Faculty of Dentistry, Cairo University
name: Mariam Aly, Phd
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01569529: Young Adult Smoker's Treatment Demand
Official title: Increasing Young Adult Smoker's Demand for Internet-based Cessation Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Smoking Cessation
Lead sponsor: University of Illinois at Chicago
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
name: University of Iowa
name: Truth Initiative
First posted: 2012-04-03
Enrollment: 3070
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Young adult Internet users

Brief summary: The purpose of this study is to determine whether tailored online advertisements will drive young adult smoker's (18 to 26 years old), who are motivated to quit, to use Internet-based cessation treatment.


Eligibility criteria: Inclusion Criteria:

* 18 to 30 years old
* smoke on some days or everyday
* enrollment in specified online cessation program

Primary outcomes:
measure: Program Enrollment
timeFrame: 1-month intervals over 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Institute for Health Reseach and Policy, UIC
state: Illinois
Study officials:
affiliation: University of Illinois at Chicago
name: Robin J Mermelstein, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Iowa
name: Susan J Curry, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05299229: Continuous Non-invasive Hemodynamic Monitoring in Early-onset Severe Preeclampsia: a Comparison of Echocardiography, Bioreactance, and Finger Cuff Measurements
Official title: Continuous Non-invasive Hemodynamic Monitoring in Early-onset Severe Preeclampsia: a Comparison of Echocardiography, Bioreactance, and Finger Cuff Measurements
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pre-Eclampsia
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2022-03-28
Enrollment: 12
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with severe preeclampsia.

Brief summary: The purpose of this study is to compare the feasibility and accuracy of two methods of non-invasive hemodynamic assessments - bioreactance as assessed by non-invasive cardiac output monitoring (NICOM; Cheetah Medical) and pulse wave analysis as assessed by finger cuff arterial pressure (ClearSite, Edwards Life Sciences) - compared to hemodynamic assessments by intermittent echocardiography in early onset preeclampsia.


Eligibility criteria: Inclusion Criteria:

* BP \>160 or DBP \>110
* gestational age between 20-34 weeks
* singleton pregnancy

Exclusion Criteria:

* prior diagnosis of chronic hypertension or hypertensive disorder of pregnancy
* multi-fetal pregnancy

Primary outcomes:
measure: Change in cardiac output (L/min) as measured by NICOM (bioreactance) monitoring
timeFrame: Baseline (typically 3-5 days before birth, but can be up to 5 weeks before birth), 3 days after birth (postpartum)
measure: Change in systemic vascular resistance (dynes/sec*cm-5) as measured by NICOM (bioreactance) monitoring
timeFrame: Baseline (typically 3-5 days before birth, but can be up to 5 weeks before birth), 3 days after birth (postpartum)
measure: Change in Cardiac output (L/min) as measured by Clearsite (pulse wave analysis) monitoring
timeFrame: Baseline (typically 3-5 days before birth, but can be up to 5 weeks before birth), 3 days after birth (postpartum)
measure: Change in Systemic vascular resistance (dynes/sec*cm-5) as measured by Clearsite (pulse wave analysis) monitoring
timeFrame: Baseline (typically 3-5 days before birth, but can be up to 5 weeks before birth), 3 days after birth (postpartum)
measure: Change in Cardiac output (L/min) as measured by transthoracic echocardiography
timeFrame: Baseline (typically 3-5 days before birth, but can be up to 5 weeks before birth), 3 days after birth (postpartum)
measure: Change in Systemic vascular resistance (dynes/sec*cm-5) as measured by transthoracic echocardiography
timeFrame: Baseline (typically 3-5 days before birth, but can be up to 5 weeks before birth), 3 days after birth (postpartum)
Secondary outcomes:
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University Hospital
state: Connecticut
Study officials:
References:
Clinical trial NCT00364429: SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
Official title: Investigation of the NMDA Receptor System in Man as a Potential Surrogate Marker for Deficit Syndrome in Schizophrenia: a [123]I-CNS 1261 Single Photon Emission Tomography (SPET) Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Schizophrenia
Keywords: schizophrenic patients
SPET
NMDA receptor
ligand [123]I-CNS 1261
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2006-08-15
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This study was designed to compare the \[123\]I-CNS 1261 binding to NMDA receptor between healthy volunteers and different subgroups of schizophrenic patients. Investigation of the potential influence of antipsychotic and concomitant medication on \[123I\] CNS 1261 binding is also relevant.Fifteen healthy subjects (male and female of non-child bearing potential) will be recruited and 40 schizophrenic patients divided in 3 subgroups as indicated before: Subgroup a) treatment-naive, (n=10); Subgroup b) on stable treatment with risperidone (without criteria of deficit syndrome on the SDS scale, (n=15);Subgroup c) on stable treatment with risperidone fitting criteria of deficit syndrome on the SDS scale, (n=15).


Eligibility criteria: Inclusion criteria:

* Right-handed
* Smoker
* Healthy volunteer or schizophrenic patients as diagnosed by DSM IV criteria.
* Treatment naive patients or with Risperidone treatment for 2 months that have not received any depot neuroleptic during the last year.
* Women of childbearing potential must agree to acceptable method of birth control.

Exclusion criteria:

* Any clinically or laboratory significant abnormality.
* Subjects receiving a radiation dose from other activities of more than 10 mSv over any 3 year period.
* Heart pacemaker, metallic prosthesis or other metallic body implants.
* History or presence of CNS conditions.
* History of substance dependence.
* History of or suffers from claustrophobia.
* Positive test for HBV (hepatitis B virus), HCV (hepatitis C virus) or HIV.
* Pregnant or lactating women.

Primary outcomes:
measure: CNS (Central Nervous System) 1261 binding differences in healthy volunteers and 3 different predefined subgroups of schizophrenic patients and in the 3 different subgroups of schizophrenic patients.
timeFrame: throughout the study
Secondary outcomes:
measure: Effect of treatment with risperidone and lorazepam in inducing changes on [123]I CNS 1261 binding, and its relationship with the plasma concentration of administered drugs and with Psychopathological scales scores.
timeFrame: throughout the study
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT06276829: Behçet and LDH/Albumin
Official title: A Convenient Parameter for Predicting Behçet's Disease Severity: Lactate Dehydrogenase/Albumin Ratio
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Behcet's Disease
Albumin
Lactate Dehydrogenase
Disease Severity
Lead sponsor: Ataturk University
Sponsor class: OTHER
First posted: 2024-02-26
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: A total of 349 subjects, including 160 patients with Behçet's disease and 189 healthy controls

Brief summary: ABSTRACT Objective: To investigate whether the lactate dehydrogenase to albumin ratio can be used as a parameter to determine disease severity in Behçet's disease, an inflammatory disease, by comparing it to healthy controls.

Patients and Methods: In this retrospective cohort study, patients with Behçet's disease aged 18-69 years who presented to the outpatient clinic between February 2020 and April 2023 and healthy individuals of similar age and gender were enrolled. LDH, albumin levels, and LDH/albumin ratio of both groups were compared. Clinical findings and characteristics of Behçet's patients and disease severity were recorded and analyzed in relation to LDH/albumin ratio.


Eligibility criteria: Inclusion Criteria:

Patients with Behçet's disease aged 18-69

Exclusion Criteria:

* younger than 18 years or older than 69 years, pregnant and lactating patients, patients with acute infection on admission or nutritional problems, symptomatic gastrointestinal symptoms, malignancy, hepatitis or liver disease were excluded.

Primary outcomes:
measure: LDH/albumin ratio
timeFrame: February 2020 and April 2023
Secondary outcomes:
Other outcomes:
Locations:
city: Erzurum
country: Turkey
facility: Erdal Pala
Study officials:
References:
Clinical trial NCT00862329: Influence of Protein Source on Satiety and Metabolism
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Healthy subjects
Lead sponsor: Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Sponsor class: OTHER
Collaborators: name: National Research Agency, France
First posted: 2009-03-16
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Dietary protein is the more satiating nutrient, however it is not clear whether satiety may be influenced by the nature of the protein. This study was designed to assess potential differences between protein sources on satiety and their relationship with digestive and metabolic kinetics.


Eligibility criteria: Inclusion Criteria:

* BMI between 25 and 30

Exclusion Criteria:

* allergy to milk proteins

Primary outcomes:
measure: satiety
timeFrame: 7 days
Secondary outcomes:
measure: hormonal profiles, digestive fluxes of nutrients, postprandial dietary N metabolism
timeFrame: 9 days
Other outcomes:
Locations:
city: Bobigny
country: France
facility: Centre de recherche sur volontaires
Study officials:
References:
citation: Marsset-Baglieri A, Fromentin G, Airinei G, Pedersen C, Leonil J, Piedcoq J, Remond D, Benamouzig R, Tome D, Gaudichon C. Milk protein fractions moderately extend the duration of satiety compared with carbohydrates independently of their digestive kinetics in overweight subjects. Br J Nutr. 2014 Aug 28;112(4):557-64. doi: 10.1017/S0007114514001470. Epub 2014 Jun 26.
citation: Boutrou R, Gaudichon C, Dupont D, Jardin J, Airinei G, Marsset-Baglieri A, Benamouzig R, Tome D, Leonil J. Sequential release of milk protein-derived bioactive peptides in the jejunum in healthy humans. Am J Clin Nutr. 2013 Jun;97(6):1314-23. doi: 10.3945/ajcn.112.055202. Epub 2013 Apr 10.
Clinical trial NCT06896929: Comparison of Permethrin and Ivermectin in Children Greater Than 6 Yrs Age for Treatment of Scabies
Official title: Comparison of Topical Permethrin 1 Day Verses 2 Day Application Versus Oral Ivermectin for Treatment of Scabies in Children Greater Than 6 Yrs of Age
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Scabies
Keywords: Comparison of permethrin and ivermectin in scabies
Lead sponsor: Children Hospital and Institute of Child Health, Lahore
Sponsor class: OTHER
First posted: 2025-03-26
Enrollment: 90
Sex: ALL
Minimum age (years): 6
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Scabies is highly contagious,pruritic infestation of skin.Various treatment modalities have been used but search for ideal scabicide is ongoing.we wnt to coduct this study to compare the outcome of permethrin verses ivermectin in children for treatment of scabies .This randomized clinical trial will be done in children hospital lahore for 12 months.Sample size of 90 cases;30 in each group will be included through non probability consecutive sampling.Then patient will be randomly divided into 3 groups.In group A patient will be given 5% permethrin topical application to whole body single application. In Group B ,patients will be given topical permethrin for twice application 24 hrs appart ,In group C patients will be given Tablet Ivermectin single dose 200microgram/kg.Then patients will be examined after 2 weeks and 4 weeks for no of lesions and pruritis and cure will be labeled.All this information will be recorded on performa .Data will be entered and analysed by using SPSS version 26.Three groups will be compared for cure by using chi-square test.P value less than and equal to 0.05 will be considered as significant.


Eligibility criteria: Inclusion Criteria:

* Age 6-15
* Both genders
* Diagnosed with scabies (as per operational definition)

Exclusion Criteria:

* Children with recurrent scabies on medical record
* Known allergy to ivermectin or permethrin.
* Widespread eczema or impetigo.
* Liver dysfunction or renal failure

Primary outcomes:
measure: Cure of scabies.
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Children Hospital Lahore
state: Punjab
Study officials:
References:
Clinical trial NCT00757029: Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)
Official title: Association Between Norepinephrine Transporter Polymorphism and Response of Methylphenidate
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Attention Deficit Disorder With Hyperactivity
Methylphenidate
Pharmacogenetics
Keywords: ADHD,
norepinephrine transporter
pharmacogenetics
Lead sponsor: Hallym University Medical Center
Sponsor class: OTHER
First posted: 2008-09-22
Enrollment: 150
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that norepinephrine transporter polymorphism is associated with responses and adverse effects of OROS-methylphenidate in treatment of ADHD.


Eligibility criteria: Inclusion Criteria:

* ADHD
* Physically healthy

Exclusion Criteria:

* Neurological illness
* Concurrent additional psychiatric treatment
* \< IQ 70
* Psychotic disorder
* Major mood disorder needed other psychiatric medication
* Significant suicidal ideation
* Pervasive developmental disorder

Primary outcomes:
measure: Korean ADHD Rating scale-parent version (KARS)
timeFrame: baseline,1,2,4,8 weeks
Secondary outcomes:
measure: Barkely side effect rating scale
timeFrame: 1,2,4,8weeks
Other outcomes:
Locations:
city: Anyang
country: Korea, Republic of
facility: Hallym University Sacred Heart Hospital
state: Gyeonggi-do
Study officials:
References:
Clinical trial NCT05898529: COVID Infection in Pediatric Surgical Patient
Official title: Prevalence of Asymptomatic COVID-19 Infection in Pediatric Surgical Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: COVID-19
Lead sponsor: Salem Anaesthesia Pain Clinic
Sponsor class: OTHER
First posted: 2023-06-12
Enrollment: 350
Sex: ALL
Minimum age (years): 2
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consecutive surgical patients, aged 2-17 years.

Brief summary: Children infected with COVID-19 are mostly asymptomatic. There is a dearth of data on the epidemiology of COVID-19 in the pediatric population. This is a prospective observational clinical study of pediatric surgical patients. COVID-19 rapid antigen testing will be performed on pediatric patients.

Detailed description: Children infected with COVID-19 are mostly asymptomatic or mildly symptomatic. Children may spread COVID-19 to the elderly, vulnerable patients and medical staff. There is a dearth of data on the epidemiology of COVID-19 in the pediatric surgical population. Rapid antigen detection tests for the diagnosis of COVID-19 are reliable, simple, fast, and inexpensive.

This is a prospective observational clinical study. The study population will include all consenting pediatric surgical patients, aged 2-17 years. Informed consent will be obtained from each patient and the legal guardian who agree to participate in the study. Nasopharyngeal swab specimens will be collected from anesthetized pediatric patients. COVID-19 rapid antigen testing will be performed according to the equipment manufacturer's instructions.

Data collection will include COVID-19 test result, nasal swab complication, patient demographics, surgical history, medical history, regular medications, COVID-19 symptoms, and COVID-19 exposure information. COVID-19 symptoms that will be recorded are cough, wheeze, nasal congestion, breathing difficulty, new loss of taste or smell, fever, chills, rigors, body aches, sore throat, nausea, and fatigue. COVID-19 exposure will be considered as being within 6 feet of a person with diagnosed COVID-19 infection in the previous 14 days.

Eligibility criteria: Inclusion Criteria:

* surgical patients aged 2-17 years
* informed consent for surgery
* no COVID-19 diagnosis in previous 6 months
* no history of nasal bleeding
* no history of coagulopathy.

Exclusion Criteria:

* patient refusal of testing
* difficulty in obtaining consent
* COVID-19 diagnosis in recent 6 month
* history of nasal bleeding
* history of coagulopathy.

Primary outcomes:
measure: Antigen test positive result
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Surrey
country: Canada
facility: Salem Anaesthesia Pain Clinic
state: British Columbia
Study officials:
affiliation: Salem Anaesthesia Pain Clinic
name: Olumuyiwa Bamgbade
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05869929: Easy Peasy: Health Effects of Supplementation With Vegetables
Official title: Health Effects of Supplementation With Vegetables
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Health Knowledge, Attitudes, Practice
Lead sponsor: University of Arizona
Sponsor class: OTHER
First posted: 2023-05-22
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The proposed study aims to test the effects of supplementing healthy individuals (with low baseline vegetable consumption) with 5 servings of vegetables (80-120g per serving) per day for 4 weeks on blood lipids and other cardiometabolic outcomes. Previous studies indicate the potential to see significant effects in this population and within this amount of time. Importantly, the investigators will also be including a weekly cooking demonstration as part of the intervention, which provides an essential hands-on participatory component and allows participants to connect with one another in a group setting, which aids in acceptability and adherence to dietary interventions. The investigators hypothesize that 4 weeks of daily supplementation with 4-5 servings of vegetables will significantly improve LDL-C and other cardiometabolic outcomes in healthy adults.


Eligibility criteria: Inclusion criteria:

* 18-65 years of age
* Consuming a typical American diet (i.e. not engaged in a structured diet)
* Willing and able to eat vegetables provided (i.e. not allergic or adverse to vegetables provided).

Exclusion criteria:

* Pregnant or lactating
* Participants who currently eat 5+ servings/cups of vegetables per day (excluding tomato paste/sauce, and fried potatoes 'French fries')
* Any condition that would interfere with the participant's data, at the study team's discretion.

Primary outcomes:
measure: LDL-C/non-HDL-C
timeFrame: 4-6 weeks
measure: Brachial and central blood pressure
timeFrame: 4-6 weeks
Secondary outcomes:
measure: Augmentation Index
timeFrame: 4-6 weeks
measure: Other lipids and lipoproteins
timeFrame: 4-6 weeks
measure: Glucose
timeFrame: 4-6 weeks
Other outcomes:
Locations:
city: Tucson
country: United States
facility: University of Arizona
state: Arizona
Study officials:
affiliation: University of Arizona
name: Ann Skulas-Ray, PhD
role: PRINCIPAL_INVESTIGATOR
References: